CA2155515A1 - Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta. - Google Patents

Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta.

Info

Publication number
CA2155515A1
CA2155515A1 CA002155515A CA2155515A CA2155515A1 CA 2155515 A1 CA2155515 A1 CA 2155515A1 CA 002155515 A CA002155515 A CA 002155515A CA 2155515 A CA2155515 A CA 2155515A CA 2155515 A1 CA2155515 A1 CA 2155515A1
Authority
CA
Canada
Prior art keywords
tgf
beta
antagonist
cells
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002155515A
Other languages
English (en)
French (fr)
Inventor
Wendy Waegell
James Dasch
Paul W. Kincade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Celtrix Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155515A1 publication Critical patent/CA2155515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002155515A 1993-02-19 1994-02-15 Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta. Abandoned CA2155515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1955693A 1993-02-19 1993-02-19
US08/019,556 1993-02-19
PCT/US1994/001634 WO1994018991A1 (en) 1993-02-19 1994-02-15 EXPANSION OF STEM CELLS IN LONG TERM BONE MARROW CULTURES BY NEUTRALIZATION OF TGF-$g(b)

Publications (1)

Publication Number Publication Date
CA2155515A1 true CA2155515A1 (en) 1994-09-01

Family

ID=21793831

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155515A Abandoned CA2155515A1 (en) 1993-02-19 1994-02-15 Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta.

Country Status (4)

Country Link
EP (1) EP0684828A4 (de)
JP (1) JPH08509859A (de)
CA (1) CA2155515A1 (de)
WO (1) WO1994018991A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ES2174868T3 (es) * 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US6207816B1 (en) * 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
CA2391657A1 (en) * 1999-01-25 2000-07-27 Seattle Biomedical Research Institute Anti-transforming growth factor beta (tgf-.beta.) treated stem cell composition and method
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
WO1991019513A1 (en) * 1990-06-20 1991-12-26 Bristol-Myers Squibb Company METHODS OF MODULATING BLOOD PRESSURE USING TGF-β AND ANTAGONISTS THEREOF

Also Published As

Publication number Publication date
JPH08509859A (ja) 1996-10-22
WO1994018991A1 (en) 1994-09-01
EP0684828A1 (de) 1995-12-06
EP0684828A4 (de) 1996-08-07

Similar Documents

Publication Publication Date Title
Tsai et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor.
Vujanovic et al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
AU665955B2 (en) Method for improving autologous transplantation
Ulich et al. Hematologic effects of stem cell factor in vivo and in vitro in rodents
US5633426A (en) In vivo use of human bone marrow for investigation and production
Ortiz de Landazuri et al. Immune response to Gross virus-induced lymphoma. III. Characteristics of the cellular immune response
Dexter et al. The regulation of haemopoiesis in long‐term bone marrow cultures: I. Role of L‐cell CSF
Boswell et al. Thy-1 antigen expression by murine high-proliferative capacity hematopoietic progenitor cells. I. Relation between sensitivity to depletion by Thy-1 antibody and stem cell generation potential.
DE69213943T2 (de) Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern
Oghiso et al. Differential induction of prostaglandin E2-dependent and-independent immune suppressor cells by tumor-derived GM-CSF and M-CSF
Kedar et al. Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF)
CA2155515A1 (en) Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta.
DE69533354T2 (de) Ausrüstung für die extrakorporale zellkultur und zelltransplantation
EP1150694B1 (de) Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode
Yankelevich et al. Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics
Sun et al. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice
Boyehansen et al. Hematopoietic growth factors for the treatment of myelodysplastic syndromes
Chabannon et al. Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamide.
DE69117974T2 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen
Wierda et al. Effects of cyclophosphamide on hemic precursor cells in mouse bone marrow and spleen
EP0483216B1 (de) Verfahren zur herstellung menschlicher adhärenter lymphokin-aktivierter killerzellen (alak)
Emerson et al. The regulation of hematopoiesis following bone marrow transplantation
WO1991002531A1 (en) Method for the modulation of haemopoiesis in a mammal
EP0910624B1 (de) Verfahren zur herstellung und vermehrung von lymphozyten
KR100562274B1 (ko) 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead